Across TCGA pan-cancer cohorts, SETMAR Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SETMAR data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SETMAR Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SETMAR expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, PRAD, and COAD are the cancer types where SETMAR Mutation most reproducibly stratifies survival.